TRiNDS is a specialized contract research organization (CRO) for neuromuscular diseases. It is a full-service CRO with four main pillars of solutions in clinical operations, data management, biostatistics, and study measurements. It is unique with its focus on muscular dystrophies and study outcome developments. It is built on the expertise established with the academic clinical trial network: CINRG. TRiNDS bridges gaps for neuromuscular research by drawing in the key leaders in the field.
2017 CureDuchenne Cares Schedule Announced
Marathon submitted New Drug Applications (NDAs) to the Food and Drug Administration (FDA) last June for deflazacort. The NDAs have been accepted for filing and review. The FDA expects […]
NEWPORT BEACH, Calif., January 16, 2017 – CureDuchenne, a nonprofit dedicated to funding research and improving patient care for Duchenne muscular dystrophy, will host a webinar with TRiNDS, a new […]
August 8, 2011 was the day we first heard the word Duchenne. Every moment of that day is etched in my memory. We were hit out of the blue with […]
NEWPORT BEACH, Calif., January 10, 2017 – CureDuchenne announced today that BioMarinPharmaceutical Inc. has transferred its Duchenne natural history database to CureDuchenne, the venture philanthropy not-for-profit organization that is leading […]
When our two sons Timothy, 13, and Andrew, 10, were diagnosed with Duchenne muscular dystrophy there was little hope. We were told there was no cure or treatment and that […]
NEWPORT BEACH, Calif., Dec. 19, 2016 – CureDuchenne Ventures, LLC, a company that funds research to find a cure for Duchenne muscular dystrophy, announced today that they invested inTRiNDS, LLC, […]
CureDuchenne has always been focused on finding and funding treatments to help EVERYONE affected with Duchenne, and to TREAT THE WHOLE DISEASE. We are very proud of our comprehensive portfolio […]
